Your browser doesn't support javascript.
loading
Selective factor VIII activation by the tissue factor-factor VIIa-factor Xa complex.
Kamikubo, Yuichi; Mendolicchio, G Loredana; Zampolli, Antonella; Marchese, Patrizia; Rothmeier, Andrea S; Orje, Jennifer Nagrampa; Gale, Andrew J; Krishnaswamy, Sriram; Gruber, András; Østergaard, Henrik; Petersen, Lars C; Ruf, Wolfram; Ruggeri, Zaverio M.
Affiliation
  • Kamikubo Y; Department of Molecular Medicine and.
  • Mendolicchio GL; MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA.
  • Zampolli A; Hemostasis and Thrombosis Research Laboratory, Humanitas Clinical and Research Center, Milan, Italy.
  • Marchese P; Department of Molecular Medicine and.
  • Rothmeier AS; MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA.
  • Orje JN; Department of Molecular Medicine and.
  • Gale AJ; MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA.
  • Krishnaswamy S; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA.
  • Gruber A; Department of Molecular Medicine and.
  • Østergaard H; MERU-Roon Research Center on Vascular Biology, The Scripps Research Institute, La Jolla, CA.
  • Petersen LC; Department of Molecular Medicine and.
  • Ruf W; Research Institute, Children's Hospital of Philadelphia, and Department of Pediatrics, University of Pennsylvania, Philadelphia, PA.
  • Ruggeri ZM; Departments of Biomedical Engineering and Medicine, Oregon Health & Science University School of Medicine, Portland, OR.
Blood ; 130(14): 1661-1670, 2017 10 05.
Article in En | MEDLINE | ID: mdl-28729433
ABSTRACT
Safe and effective antithrombotic therapy requires understanding of mechanisms that contribute to pathological thrombosis but have a lesser impact on hemostasis. We found that the extrinsic tissue factor (TF) coagulation initiation complex can selectively activate the antihemophilic cofactor, FVIII, triggering the hemostatic intrinsic coagulation pathway independently of thrombin feedback loops. In a mouse model with a relatively mild thrombogenic lesion, TF-dependent FVIII activation sets the threshold for thrombus formation through contact phase-generated FIXa. In vitro, FXa stably associated with TF-FVIIa activates FVIII, but not FV. Moreover, nascent FXa product of TF-FVIIa can transiently escape the slow kinetics of Kunitz-type inhibition by TF pathway inhibitor and preferentially activates FVIII over FV. Thus, TF synergistically primes FIXa-dependent thrombin generation independently of cofactor activation by thrombin. Accordingly, FVIIa mutants deficient in direct TF-dependent thrombin generation, but preserving FVIIIa generation by nascent FXa, can support intrinsic pathway coagulation. In ex vivo flowing blood, a TF-FVIIa mutant complex with impaired free FXa generation but activating both FVIII and FIX supports efficient FVIII-dependent thrombus formation. Thus, a previously unrecognized TF-initiated pathway directly yielding FVIIIa-FIXa intrinsic tenase complex may be prohemostatic before further coagulation amplification by thrombin-dependent feedback loops enhances the risk of thrombosis.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Coagulation / Factor VIII / Thromboplastin / Factor VIIa / Factor Xa Type of study: Prognostic_studies Limits: Humans Language: En Journal: Blood Year: 2017 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Coagulation / Factor VIII / Thromboplastin / Factor VIIa / Factor Xa Type of study: Prognostic_studies Limits: Humans Language: En Journal: Blood Year: 2017 Type: Article